NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
What is the ticker symbol for NexImmune, Inc.? What does NEXI stand for in stocks?
NEXI is the stock ticker symbol of NexImmune, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of NexImmune, Inc. (NEXI)?
As of Thu Dec 19 2024, market cap of NexImmune, Inc. is 376.56 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of NEXI stock?
You can check NEXI's fair value in chart for subscribers.
Is NexImmune, Inc. a good stock to buy?
The fair value guage provides a quick view whether NEXI is over valued or under valued. Whether NexImmune, Inc. is cheap or expensive depends on the assumptions which impact NexImmune, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NEXI.